Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Timothy Kross who wrote (2701)	11/8/1997 3:28:00 PM
From: Oliver & Co	Respond to of 6136

It has been shown that the ammount of HIV RNA found in blood is directly related to the HIV found in Lymphoid tissue. Therefore the only way we will be able to say whether or not there is no replication is when we have a test down to "0" copies. The number of copies under the level of detection is very important, because when a patient is under treatment that should tell you the resistance. Treatment will stop replication of wild virus, but if there is mutant (resistant) virus that will replicate, maybe the level of replication will be low, but if there is any mutant being replicated, that will only increase over time. Blood from the patients of the study you quoted was given to Dr. Richman, San Diego. And he found that CD45RO(memory) cells present in that blood contained replication-competent integrated provirus, which could be activated to yield infectious virus even after 2 years of "undetectable" HIV RNA. Remember "HAART" now, "FAART" in the future. Interesting. Regards, JLL